93 A recent study has identified a crucial biomarker that could help predict survival outcomes for patients with ampullary carcinoma, a rare type of gastrointestinal cancer. The research, conducted by a team at Sun Yat-sen University Cancer Center, suggests that the C-reactive protein–albumin–lymphocyte (CALLY) index serves as a reliable indicator of prognosis following surgery. The findings were published in the Journal of Inflammation Research. Ampullary carcinoma arises in the ampulla of Vater, a small region where the bile duct and pancreatic duct meet the small intestine. It represents a small fraction of gastrointestinal malignancies but has a higher surgical resection rate than other periampullary cancers. The primary treatment is pancreaticoduodenectomy, commonly known as the Whipple procedure, which removes the tumour along with parts of the pancreas, intestine, and bile duct. However, despite surgical intervention, long-term survival remains uncertain, with five-year survival rates ranging from 35 to 50 per cent. The study analysed data from 201 patients who underwent surgery for ampullary carcinoma. Researchers examined several clinical and pathological factors, including tumour stage, lymph node involvement, and postoperative treatment. They found that the CALLY index, which reflects inflammatory and nutritional status, was significantly associated with survival outcomes. A lower CALLY index correlated with poorer cancer-specific survival, highlighting its potential role in guiding post-surgical management. Inflammation has long been recognised as a factor in cancer progression. Chronic inflammation can promote tumour growth, while malnutrition often worsens patient outcomes. The CALLY index incorporates C-reactive protein, albumin, and lymphocyte levels to provide a more comprehensive assessment of a patient’s immune and nutritional status. Previous studies have shown its prognostic value in various malignancies, but this research is among the first to establish its significance in ampullary carcinoma. The findings suggest that patients with a higher CALLY index—indicating lower inflammation and better nutritional status—have better survival rates. Even after adjusting for other variables such as tumour size and lymph node involvement, the CALLY index remained an independent predictor of prognosis. This could provide clinicians with a simple yet effective tool for identifying high-risk patients who may benefit from closer monitoring or additional treatment. The study also reinforced the importance of other established prognostic factors, including tumour stage and lymph node metastasis. Patients with more advanced disease at the time of surgery had significantly lower survival rates. The role of adjuvant chemotherapy remains a subject of debate, but findings suggest that patients receiving gemcitabine-based or S-1-based regimens had improved survival outcomes compared to those who did not undergo chemotherapy. Despite its promising findings, the study has limitations. It was conducted at a single institution with a relatively small sample size, meaning further research is needed to validate the results in larger, multi-centre studies. Nonetheless, the identification of the CALLY index as a prognostic marker offers a valuable step forward in refining treatment strategies for this rare cancer.